Safety and Efficacy of Drug Combinations Against Trichuris Trichiura

DBL -Institute for Health Research and Development750 enrolled

Overview

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB and MBD each in combination with IVM in the treatment of Trichuris trichiura in children aged 5-14 years.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

750

Conditions

Parasitic Diseases

Interventions

albendazoleDRUG

albendazole (400 mg on dose)

mebendazoleDRUG

mebendazole (500 mg one dose)

ivermectinDRUG

ivermectin (200 microgram/kg body weight)

albendazole + ivermectin

Eligibility

Sex: ALLMin age: 5 YearsMax age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Those who are enrolled in class one to six * Are infected with T. trichiura * Whose parent consent and who are willing to participate Exclusion Criteria: * Those with acute and chronic diseases other than T. trichiura * Those with a history of any serious adverse drug reactions

Locations (1)

Vector Control Division

Kampala, Uganda

Outcomes

Primary Outcomes

Record adverse reactions

Time frame: 6 weeks

Secondary Outcomes

Efficacy of treatment

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.